Viagra switch to OTC status in the UK

RNS Number : 8580X

N4 Pharma PLC

29 November 2017

 

29 November 2017

N4 Pharma Plc

("N4 Pharma" or the "Company")

Viagra switch to OTC status in the UK

N4 Pharma Plc (AIM: N4P), a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance, welcomes the announcement of the move to make Viagra 50mg available as an Over The Counter ("OTC") product in the UK.

Nigel Theobald, CEO of N4 Pharma, commented:

"Unlike in the USA, prescription products cannot be advertised directly to consumers in Europe and this move to OTC will make that possible in the UK for sildenafil.

The establishment of an OTC market for sildenafil in the UK will bring many opportunities for reformulated products as has happened in other OTC sectors. If this OTC status is widely supported by pharmacists in the UK, our 50mg reformulation of sildenafil will also be able to apply for OTC status.

The move is a great endorsement for our decision to reformulate sildenafil."

Enquiries:

N4 Pharma Plc Nigel Theobald, CEO,	Via Alma PR
Stockdale Securities Tom Griffiths	Tel: [phone]
Beaufort Securities Elliot Hance	Tel: [phone]
Alma PR Josh Royston Robyn Fisher	Tel: [phone] Tel: [phone]

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance.

N4 Pharma's reformulation work falls under two divisions:

• generic, already commercialised, drugs; and

• delivery of novel and existing vaccines.

N4 Pharma has identified a number of established drugs that could be improved upon through its reformulation techniques. N4 Pharma's most advanced reformulation is for sildenafil, widely marketed as Viagra, where N4 Pharma is seeking to improve the speed at which the drug takes effect whilst also extending its duration of action.

N4 Pharma's reformulation approach should take approximately three years to obtain regulatory approval as opposed to the traditional process for new drugs of on average ten years. The cost and risk profile of this model is also significantly less than the traditional process. N4 Pharma's business model for generics is to take reformulated drugs from its portfolio through to the stage where it will license its newly reformulated drugs to pharmaceutical companies to commercialise them. N4 Pharma's revenues should be derived from up front milestone and royalty payments associated with the licence.

N4 Pharma's business model for vaccines is to undertake the required clinical work to demonstrate the capability of its delivery system as a cancer vaccine or therapeutic treatment so that it can license the technology to major players developing treatments in this area, again in return for up front milestone and royalty payments associated with the licence.

 

END

 

 

NRABLBBTMBBTBMR